AP-1 transactivation appears to be required for mouse JB6 cell neoplastic transformation induced by the tumor promoter TPA or epidermal growth factor (EGF). Exposure to AP-1 transrepressing retinoids and glucocorticoids and expression of a dominant negative c-jun (TAM67) blocked tumor promoter-induced AP-1 transactivation and neoplastic transformation. The aim of the present study was to extend the inquiry of the role of AP-1 and other transcription factors to human neoplastic progression. Expression of human papillomavirus (HPV) 16 or 18 E6 and E7 immortalizes human keratinocytes and inhibits serum/calcium-stimulated dierentiation. Further transformation by v-fos coexpression renders these keratinocytes tumorigenic in nude mice. We have analysed two series of E6/E7 immortalized human keratinocyte cell lines that show progressing phenotypes ranging from dierentiation sensitive to anchorage-independent to tumorigenic in nude mice. We analysed the activities of AP-1 and NFkB which may`cross-talk'. Both DNA binding and transactivation of AP-1 and NF-kB transcription factors showed elevation in the anchorage-independent (16RH) and tumorigenic (18 v-fos) keratinocyte lines compared to the less progressed but immortalized cell lines. HPV E7 was expressed at a constant level shown by quantitative RT-PCR in both the more and the less progressed lines, indicating that E7 is not the factor limiting this progression. Blocked shift/supershift analysis indicates that Fos family member proteins especially Fra-1 and Fra-2 are related to progression and no changes found in the Jun family member proteins although they are present in the AP-1/DNA binding complex. When a dominant negative mutant cjun driven by a human keratin 14 promoter was cotransfected with AP-1 or NF-kB reporters, both AP-1 and NF-kB activities were suppressed in the more progressed cell lines 16RH and 18 v-fos but not in the less progressed 16RL or 18 cell lines. Overexpression of the same dominant negative c-jun did not inhibit p53 dependent reporter transactivation, indicating the speci®city of inhibition of AP-1 and NF-kB transactivation in the HPV-immortalized cells. Stable transfectants of this mutant c-jun in the two more progressed cell lines 16RH and 18 v-fos showed reduced AP-1 and NF-kB activation and reduced anchorage-independent growth. Together, these results indicate that activation of AP-1, NF-kB or both may contribute to neoplastic progression in HPV immortalized human keratinocytes and that speci®c targeting of the elevated levels seen in benign or malignant tumors might be eective for prevention or treatment of human cancer.
Introduction
The multistep nature of tumor formation is an accepted paradigm for carcinogenesis which involves initiation, promotion, and progression (Drinkwater et al., 1989; Fearon et al., 1990; Weinberg et al., 1989) . The JB6 mouse epidermal clonal genetic variant cell lines that are tumor promotion sensitive (P+), resistant (P7) or transformed derivatives (Tx) provide a suitable in vitro model for studying the signaling in neoplastic transformation (Colburn et al., 1979 (Colburn et al., , 1981 (Colburn et al., , 1982 . By using these cell lines, we have demonstrated a causal relationship between tumor promoter-induced neoplastic transformation and transcription factor AP-1 transactivation with the following evidence: (a) c-Jun expression and AP-1 transactivation are induced in P+ cells but not P7 cells by TPA or EGF (Bernstein and Colburn, 1989) . (b) Inhibition of AP-1 expression by a dominant negative mutant c-Jun (TAM67) or by AP-1 transrepressing retinoid blocks TPA-or EGF-induced AP-1 transactivation and cell transformation (Dong et al., 1994; Li et al., 1996) . (c) TAM67 expression blocks progression in mouse papilloma keratinocytes (Dong et al., 1997) .
HPV16 and HPV18 are members of a high-risk HPV group present in high-grade cervical intraepithelial neoplasia and malignant cervical disease. Although expression of high risk HPV E6 and E7 may be necessary, additional alterations must occur for progression to tumorigenicity (Hurlin et al., 1991) . Expression of HPV16 E6 and E7 proteins immortalizes human keratinocytes in vitro (Hawley-Nelson et al., 1989; Wilding et al., 1996) and co-expression of HPV18 and v-fos transforms keratinocytes to carcinoma phenotype (Schlegel et al., 1988; Pei et al., 1993) . HPV16 and HPV18 encoded E6 and E7 interact with p53 and pRB to inactivate these tumor suppressor proteins (Dyson et al., 1989; Munger et al., 1989a; Werness et al., 1990) . E6/E7 expression activates epidermal growth factor receptor expression (Wilding et al., 1996) . Antinore et al. (1996) have reported that the HPV16 E7 gene product interacts with and transactivates the AP-1 transcription factor. Although all these factors may contribute to cell transformation, p53 induced transactivation may function primarily to suppress cell growth (Crook et al., 1994) . Inactivation of p53 and pRb is sometimes insucient for cell immortalization (Chen et al., 1993) and is generally insucient and sometimes unnecessary for transformation. Although benign to malignant tumor progression is accompanied by inactivation of p53 in the classical initiation-promotion model of skin carcinogenesis (Kemp et al., 1994) , transgenic mice expressing epidermis-targeted v-fos form papillomas and carcinomas without p53 mutations (Greenhalgh et al., 1995) . These observations suggest that in addition to E6/E7-mediated tumor suppressor gene inhibition, the role of signal transduction by AP-1 and other transcription factor(s) induced during neoplastic progression needs to be further investigated.
Both AP-1 and NF-kB are heterodimeric nuclear transcription factors. AP-1 contains proteins of two major families, Jun and Fos, consisting of c-Jun, Jun B, Jun D and c-Fos, Fos B, Fra-1 (Fos-related antigen-1) and Fra-2 family members, (Angel and Karin, 1991) . Many stimuli including tumor promoters regulate AP-1 binding to the consensus AP-1 binding sequence and stimulate target gene transcription. Some of these AP-1 regulated gene transcripts may mediate neoplastic transformation (Angel et al., 1987; Lee et al., 1987) . NF-kB consists of a multigene family comprised of ®ve major members: p50, p65(Rel A), c-Rel, p52 and Rel B (Baeuerle and Baltimore, 1996; Nolan and Baltimore, 1992) . The most abundant dimer of the inducible NFkB is a p50/p65 heterodimer (Baeuerle et al., 1991) . Under unstimulated conditions, NF-kB is quiescent in the cytoplasm in combination with IkB and activated when dissociated from IkB in response to a variety of stimuli including viruses, bacteria, radiation, oxidants and cytokines such as TNF-a (Baeuerle and Henkel, 1994) . Disruption of IkB by overexpressing antisense RNA activated NF-kB binding activity and induced cell transformation (Beauparlant et al., 1994) . Interestingly, interaction of NF-kB subunit p65 with AP-1 subunit cJun can lead to a synergized potential of both AP-1 and NF-kB transactivation (Stein et al., 1993) .
Expression of a dominant negative c-jun mutant in which the transactivation domain is deleted blocks Haras/c-jun-induced transformation Brown et al., 1993) and tumor promoter induced transformation in the mouse JB6 model (Dong et al., 1994) . Expression of the same mutant c-jun driven by a human keratin 14 promoter inhibits both AP-1 and NF-kB transactivation and induced invasion in mouse keratinocytes (Dong et al., 1997) . In order to extend our studies of the role of AP-1 and NF-kB activation to a human keratinocyte model of neoplastic progression we have analysed a series of HPV E6/E7 immortalized human keratinocyte cell lines that show progression phenotypes ranging from dierentiation sensitive to anchorage-independent to tumorigenic in nude mice. Using luciferase reporter and gel shift assays we demonstrate that both AP-1 and NF-kB showed elevated activation in the more progressed cell lines. Stable expression of the AP-1 inhibiting dominant negative Jun speci®cally inhibited AP-1, NF-kB and anchorage-independent growth, suggesting for the ®rst time that both AP-1 and NF-kB activation may be required in the neoplastic progression of HPVimmortalized human keratinocytes.
Results
Elevated AP-1 and NF-kB activities in anchorageindependent and tumorigenic human keratinocyte lines Two progression series of HPV immortalized human keratinocyte lines were studied: one was immortalized by HPV16 E6/E7 transfection (Hawley-Nelson et al., 1989) and the other, by transfection of HPV18 genome with or without v-fos cDNA (Pei et al., 1993) . The phenotypes of these two series are listed in Figure 1 . The two progression series include stable lines that are dierentiation sensitive, dierentiation resistant but Figure 1 Progressive elevation of AP-1 (a, b) and NF-kB (c, d) transactivation in two series of HPV immortalized human keratinocytes. Fifty thousand cells of HPV16 or HPV18 immortalized cell lines were grown in 12-well cell culture dish for 24 h before transfection with collagenase-AP-1 luciferase reporter or HIV-NF-kB luciferase reporter and b-galactosidase reporter by LipofectAMINE as described in Materials and methods. Luciferase activity was measured 36 h following DNA transfection using 100 ml of cell lysate and 100 ml luciferase assay reagent. An aliquot of the same cell lysate of each cell line was used for measurement of b-galactosidase activity and the results were used for normalization of luciferase activity. Data presents the mean+s.e.m. of three transfection experiments. (a, c) HPV-16 E6/E7 immortalized keratinocyte lines (16SL, 16SH, 16RL, and 16RH presents calcium sensitive low passage, calcium sensitive high passage, calcium resistant low passage, and calcium resistant high passage lines respectively; Note only 16RH grows anchorage independently). (b, d) HPV18 immortalized (18) and HPV18 v-fos transformed (18 v-fos) keratinocyte cell line. (e, f) P53 luciferase and b-galactosidase reporters were co-transfected in HPV16 (e) or HPV18 (f) cell line series. The luciferase activity was measured and normalized as in a ± d anchorage dependent, anchorage independent, and carcinomagenic. To determine AP-1, NF-kB, and p53 transactivation, luciferase reporters driven by AP-1, NF-kB, or p53 dependent promoters were co-transfected with b-galactosidase reporter and luciferase activity was measured at indicated times following transfection. Figure 1a shows that the 16RH cell line which is resistant to calcium-induced dierentiation and grows anchorage-independently, showed elevated collagenase-luciferase AP-1 transactivation (3.0 ± 4.5-fold) compared to the three less progressed anchoragedependent cell lines 16SL, 16SH, and 16RL. Although the cellular response to induced dierentiation varied among the three less progressed cell lines, the AP-1 activities were not changed, indicating that elevated AP-1 activation is not required for acquisition of differentiation resistance in the 16SL/H to 16RL conversion. A 5.4-fold AP-1 elevation was also seen in the tumorigenic v-fos transformed HPV18 immortalized human keratinocytes compared to the controls lacking v-fos (Figure 1b) . HIV-NF-kB driven luciferase activity showed similar elevations in the more progressed lines 16RH (4.6 ± 5.5-fold) and 18 v-fos (2.7-fold) compared to the anchorage-dependent cell lines (Figure 1c and d) . In order to determine the speci®city of these two transcription factor elevations, a control luciferase reporter driven by a p53 dependent promoter without AP-1 or NF-kB binding sites was co-transfected with bgalactosidase reporters. Despite the p53 inactivating eect of E6 expression in these cells, the p53 concentration was sucient to support signi®cant transactivation of the pG13-Luciferase reporter. No signi®cant dierence in p53 dependent transactivation was observed when comparing the more progressed lines (16RH and 18 v-fos) with the less progressed lines (Figure 1e and f) . To determine the DNA-binding activity of nuclear protein to AP-1 and NF-kB sites, EMSA was performed using the nuclear extracts from these two progression series of cell lines (Figure 2 ). Both AP-1 (Figure 2 ) and NF-kB (Figure 2b ) DNA binding activities were increased in the more progressed E6/E7 keratinocyte line 16RH and the tumorigenic line 18 v-fos compared to the less progressed cell lines of each series. DNA-binding activity was increased in 16RH cells by 3.2 and 2.4-fold for AP-1 and NF-kB respectively compared to the less progressed 16SL cell line ( Figure  2a and b) . Nuclear protein from the 16 RL cells which are resistant to calcium-induced dierentiation but grow anchorage-dependently showed no dierence in AP-1 binding activity compared to the 16SL cells but showed only 40% of the NF-kB activity (40% ± 60% detected in second and third experiments) seen in the 16SL cell line (Figure 2a and b) . This paralleled the 50% reduction in NF-kB reporter activity (Figure 1 ) seen in 16 RL cells. The tumorigenic HPV18/v-fos transformed cell line showed 7.1 and 7.8-fold increases for AP-1 and NF-kB binding respectively compared to its own control cell line 18. Thus both DNA binding and transactivation of AP-1 and NF-kB were substantially increased in the anchorage independent and the tumorigenic human keratinocyte cell lines. It is noteworthy that additional slowly migrating NF-kB complexes were seen in the 16RH and 18 v-fos cells (Figure 2b ), indicating a dierence in NF-kB composition in the more progressed cells. These additional species of NF-kB complexes may contribute to the progressed phenotype.
E7 expression is not the factor limiting the progression phenotype or the AP-1 activation E6/E7 oncoprotein expression is sucient for HPVinduced keratinocyte immortalization, and contributes Figure 2 Elevation of AP-1 and NF-kB DNA binding activity in anchorage-independent and transformed cell lines. HPV16 (SL, SH, RL, RH) and HPV18 (18, 18 v-fos) cell lines were grown in 100 mm cell culture dishes (5610 6 cells per dish) for 36 h and nuclear proteins of each cell line were extracted as described in Materials and methods. EMSA was performed using 3 mg of the same nuclear extract and 3610 4 c.p.m.
32
P-labeled AP-1 (5'-CGCTTGATGAGTCAGCCGGAA-3') (a) or NF-kB (5'-AGTTGAGGGGACTTTCCCAGGC-3') (b) oligonucleotide probes. DNA-protein complexes were separated by 6% acrylamide gel electrophoresis. Speci®city of binding was determined in the control (c) by using 1006excess of non-radioactive AP-1 or NF-kB oligonucleotide. An Sp-1 oligonucleotide did not compete with AP-1 or NF-kB oligos for binding. Quantitation of DNA binding activity of AP-1 and NF-kB indicated was estimated by radioactivity scanner or densitometry and normalized to the value of the less progressed control cell line SL and 18 respectively. Similar fold changes were obtained in two additional experiments to oncogenic transformation (Hawley-Nelson et al., 1989; Munger et al., 1989b) . This oncogenic eect has been related to inhibition of tumor suppressors p53 and pRb (Dyson et al., 1989; Munger et al., 1989a; Werness et al., 1990) . Recent results indicate that E7 also interacts with AP-1 family proteins to enhance transactivation of AP-1 dependent gene expression (Antinore et al., 1996) . In order to assess the possible contributions of E6/E7 oncoproteins to progression in these two HPV immortalized cell series, we compared E6/E7 transcript levels in the more and less progressed cell lines from the two HPV-immortalized series by RT-PCR using primers for HPV16 E7 or HPV18 E6/E7 transcripts. Figure 3a shows that E7 transcripts were expressed at a constant level in the HPV16 E6/E7 immortalized 4-cell series and E6/E7 transcript levels were also constant in the HPV18 pair. For quantitation, radioactively-labeled E7 (HPV16 series) or E6/E7 (HPV18 series) products were measured at varied numbers of PCR cycles (0 ± 40). As seen in Figure 3b and c, E7 or E6/E7 transcripts maintained a constant level in all cell lines in both series tested (Figure 3b and c). These results exclude the possibility that elevated E6/ E7 expression drives progression to dierentiation resistance, to anchorage independence, to tumorigenic phenotype or to elevated transcription factor activation. v-fos cell lines respectively. Lanes 5 and 9 were controls using RNA from 16RH or 18 v-fos) without reverse transcriptase. Lanes 6 and 10 were blank controls. Same samples were reacted with GAPDH primers as controls. (b) and (c) Quantitation of E7 and E6/E7 RT ± PCR products. E7 (HPV16 series) and E6/E7 (HPV18 series) transcripts were measured by 32 P-dCTP-labeled RT ± PCR using E7 primers for HPV16 or E6/E7 primers for HPV18 as described in Materials and methods. (b) shows an autoradiograph of E7 and E6/E7 RT ± PCR product at 30 cycles. Lanes 1 ± 4 were E7 fragments produced in 16SL, 16SH, 16RL, 16RH and lanes 7, 8 were E6/ E7 fragments produced in 18 and 18 v-fos cell lines respectively. Lanes 5, 6 and 9, 10 were the same controls indicated in (a). (c) shows the quantitation by radioactivity detector for labeled E7 or E6/E7 products as shown in (b) at 0 ± 40 cycles. Data was normalized and presented as percentage of the activity at 40 cycles transformation. In the JB6 mouse skin cell progression model overexpression of c-jun enhances cell transformation (Watts et al., 1995) . AP-1 complexes functional in the JB6 transformation response to TPA contained c-Jun, Jun B, and Jun D (Li et al., 1997) . A decrease in (putatively inhibitory) Jun B was found in radiation transformed mouse keratinocytes compared to the benign counterpart mouse 308 keratinocytes (Joselo and Bowden, 1997) . In order to determine whether progressive changes occurred in AP-1 DNA-binding complexes in the human keratinocyte progression series, we performed EMSA with speci®c Jun and Fos antibodies. Figure 4 shows the assay of blocked/ supershift using Jun antibodies (a to c) and Fos antibodies (d to f). With the exception of Jun B in the HPV18 series, c-Jun, Jun B, and Jun D proteins all are detected in both the less and the more progressed cell lines. Although the peptide epitopes to which the speci®c Jun or Fos antibodies bind are not within the DNA binding domain, the anti c-Jun, anti Jun B, anti c-Fos, and anti Fra-2 antibodies produce blocked shifts rather than supershifts, while the anti Jun D and anti Fra-2 produce a supershift. Similar results have been reported by others (Rosenberger and Bowden, 1996; Joselo and Bowden, 1997; Yamagata et al., 1997) . Figure 4b shows that while Jun B was present in the HPV16 series AP-1 complexes, it appeared to be absent from the HPV18 series AP-1/DNA complexes. The fact that nearly complete blocks were seen in the less progressed lines with anti c-Jun and anti Jun B suggests that these two Juns were major components of AP-1 complexes. Jun D may be a minor component since substantial complex remained unshifted by increasing antibody concentration (up to 1 mg per reaction, Figure 4c ). Figure 4d , e and f show that cFos/v-Fos and Fra-1 are present in both progressed cell lines 16RH and 18 v-fos but not in the two less progressed lines 16RL and 18. Since 18 v-fos line was transfected with FBJ/R v-fos gene which carries the epitope recognized by the anti c-Fos antibody (sc-52x, Santa Cruz), the Fos components detected in 18 v-fos cells in Figure 4d may consist entirely of v-Fos. In contrast, Fra-2 was detected only in the 18 v-fos line. These data support the conclusion that although Jun family members are present in the AP-1 complex, only the Fos family members especially Fra-1 and Fra-2 increase with progression. Thus Fra-1 and Fra-2 may be limiting factors for AP-1 activity in early stages of human keratinocyte transformation. These AP-1 subunits may be the target proteins for AP-1 transrepression by TAM.
Expression of a dominant negative c-Jun driven by keratin 14 promoter inhibited both AP-1 and NF-kB dependent transcriptional activity in the more-but not the less-progressed cell lines Keratin 14 promoter driven gene expression is targeted to keratinocytes. Tissue-speci®c and dierentiationspeci®c expression of human K14 promoter driven genes occurs in transgenic mice (Stellmach et al., 1991; Vassar and Fuchs, 1991; Cheng et al., 1992) . Using the JB6 skin cell progression model we have shown that expression of dominant negative c-jun gene inhibits tumor promoter induced AP-1 transactivation and cell transformation (Dong et al., 1994) and using 308 mouse papilloma keratinocytes we have shown inhibition of both transcription factors and matrigel invasion (Dong et al., 1997) . In the present study, the same mutant c-jun gene driven by a keratin 14 Fos family but not Jun family components of the AP-1 complex change with keratinocyte progression. In order to determine the compositions of the AP-1 complex in the less and the more progressed HPV immortalized keratinocytes, supershift EMSA of AP-1 using Jun and Fos family antibodies were performed with the nuclear extracts from 16RL and 16RH or 18 and 1v8-fos cell lines. Three to ®ve micrograms of nuclear protein were incubated with antibodies to c-Jun (a), Jun B (b), Jun D (c), c-Fos, (d), Fra-1 (e), and Fra-2 (f) at the indicated concentrations followed by EMSA using 3610 4 c.p.m.
Plabeled collagenase AP-1 oligonucleotide for each reaction. DNA-protein complexes were separated by 6% polyacrylamide gel electrophoresis. (c) indicates competition controls using 16RH or 18 v-fos nuclear extracts and 1006excess of unlabeled AP-1 oligonucleotides. The data presented represent one of 3 ± 5 repeats with separate nuclear extracts promoter was co-transfected with AP-1 or NF-kB reporters into the two more progressed cell lines 16RH and 18 v-fos. Figure 5 demonstrates that transcriptional activation of AP-1 and NF-kB in the two more progressed lines (16RH, Figure 5a and c and 18 v-fos, Figure 5b and d) was inhibited by expression of this dominant negative c-jun (TAM67). In contrast, cotransfection with p53 dependent promoter reporter (without AP-1 and NF-kB binding sites) and K14-TAM67 showed no change in reporter activity (data not shown). It is noteworthy that K14-TAM67 expression inhibited most of the`elevated' AP-1 and NF-kB activities in the more progressed cell lines 16RH and 18 v-fos, but did not inhibit the`unelevated' AP-1 and NF-kB activities in the less progressed 16RL and 18 cells ( Figure 5 ). These results suggest that elevated levels of NF-kB as well as AP-1 transactivation may be required for progression. They also indicate that N-terminal truncated c-Jun can inhibit NF-kB activation either directly or indirectly through known Jun/Fos interactions. Inhibition of elevated AP-1 and NF-kB may be eective for the reversion of benign or malignant phenotype while not aecting relatively normal cells.
Anchorage-independent growth was inhibited in 16RH and 18 v-fos cell lines stably expressing dominant negative c-jun
In order to determine whether inhibiting AP-1 and/or NF-kB would also suppress expression of progressed phenotypes, K14-TAM or K14-empty construct was stably co-transfected with selective hygromycin resistance plasmid into the two more progressed cell lines 16RH and 18 v-fos. To determine the expression of the mutant c-jun, immunoprecipitation and Western analyses were performed using C-terminal Jun antibody. Figure 6 shows that the 29 kDa mutant c-Jun TAM67 was expressed in the 16RH (Figure 6a ) and 18 v-fos (Figure 6b ) transfectants at levels that were less than and greater than c-Jun respectively. The K14-empty vector transfectants and the parental 16RH or 18 v-fos cell lines were included as controls (Figure 6a  and b) . To test the eect of the mutant c-jun expression on anchorage-independent growth, soft agar culture was performed with the K14-TAM transfectants. Figure 7 shows 54% and 61% inhibition of anchorage-independent colony yield in 16RH-TAM and 18 v-fos-TAM transfectants compared to the Figure 5 Expression of a dominant negative mutant c-jun (TAM67) driven by a human keratin 14 promoter blocked AP-1 (a, b) and NF-kB (c, d) activities in HPV16 anchorage-independent and HPV18/v-fos tumorigenic lines but not in the less progressed lines. HPV16(16SH and 16RH) and HPV18(18 and 18 v-fos) cell lines were co-transfected with collagenase-AP-1 luciferase reporter (AP) or HIV-NF-kB luciferase reporter (NF) with K14-TAM67 plasmid (TAM) and b-galactosidase reporter (beta) by using LipofectAMINE as described in the legend of Figure 1 . Plasmid pGem3z was the empty vector used as a vector control for K14-TAM transfection. Luciferase activity was measured 36 h following transfection and the value was normalized to b-galactosidase activity. Data presents the mean+s.e.m. of three transfection experiments vector control 16RH and 18 v-fos cell lines. AP-1 and NF-kB transactivation were also measured in these TAM transfectants by transient transfection of AP-1-luciferase or NF-kB-luciferase reporters with bgalactosidase reporter constructs. For a speci®city of transactivation control, p53-luciferase reporter was cotransfected similarly with b-galactosidase reporter. The relative transactivation activity normalized to bgalactosidase activity showed 66% and 74% reductions for AP-1 and NF-kB activity respectively in 16RH-TAM transfectants and 70% and 78% reductions in 18 v-fos-TAM transfectants compared to vector controls (Figure 7) . No elevation or inhibition of p53 dependent transactivation was detected in the 16RH-TAM and 18 v-fos-TAM transfectants compared to the vector control transfectants and parental 16RH or 18-fos cell lines (Figure 7) . The fact that more AP-1/NF-kB transcriptional inhibition (66 ± 78%) was obtained than inhibition of anchorage-independent growth (54 ± 61%), suggests that other factors may also contribute to maintenance of anchorage independent phenotype. This may also result from the heterogenicity of the pooled transfected clones which may contain clones with low or lack of TAM expression. Study on TAM expression by a tight-controlled gene induction system is underway.
AP-1 binding activity was not decreased in the TAM67 stable transfectants
The mutant c-jun gene (TAM) used in this study was a deleted form missing the N-terminal transactivation domain but retaining the DNA binding and leucine zipper domains . In order to ascertain whether AP-1 transrepression induced by overexpression of TAM involved decreased DNA binding by active (i.e. non TAM-TAM) complexes, we measured the AP-1 DNA binding activity in the TAM transfectants by EMSA and blocked/supershifts using an N-terminal c-Jun speci®c antibody. . Sixty microgram of protein were ®rst immunoprecipitated with 2 mg rabbit antimouse c-Jun antibody (Santa Cruz Co., sc-44x) and 20 ml protein A-sepharose gel at 48C overnight and the complexes were dissociated. The eluted proteins were size-separated by 12.5% polyacrymide SDS gel electrophoresis, transfered onto an Immobilon membrane and the blots were reacted with a 1 : 500 dilution of rabbit anti-mouse c-Jun antibody followed by a 1 : 5000 dilution of goat anti-rabbit IgG antibody conjugated with peroxidase. The blot was visualized by exposure to Kodak ®lm after reaction with ECL solution v-fos Figure 7 AP-1 and NF-kB activities and anchorage-independent growth were decreased in the 16RH and 18-fos K14-TAM stable transfectants. Ten thousand K14-TAM transfectants (16RH/TAM or 18-fos/TAM), control vector (16RH/pGem3z or 18 v-fos/ pGem3z) or untransfected parental cell lines (RH16 or 18 v-fos) were suspended in 1.5 ml 0.4% agar in KGM (16RH) or 1 : 1 KGM : DMEM medium (18 v-fos) over 7 ml 0.6% agar KGM medium. The cultures were maintained in a 378C incubator with 10% CO 2 for 21 days and anchorage independent colonies greater than 25 cells were scored by a computerized image analyser. The yield of anchorage-independent colonies in the TAM or control vector stable transfectants is presented relative to that for the parental cell line 16RH or 18 v-fos. The data represent the mean and standard error of three soft agar tests of stable transfectants. An independent transfection gave similar results. AP-1 and NF-kB reporter activities were normalized to b-galactosidase activity and expressed relative to that in the parental cell line (16RH or 18 v-fos) of some of the many possible species of Jun/Fos or TAM containing heterodimers. AP-1 DNA binding activity was increased with nuclei of both 16RH-TAM and 18 v-fos-TAM transfectants (estimated 2.8 and 5.1-fold for 16RH-TAM and 18 v-fos-TAM respectively compared to the vector control transfectants, Figure 8 ). c-Jun speci®c antibody (to an N-terminal epitope lacking in TAM67) blocked both the increased AP-1 binding activity in TAM-transfectants and the basal AP-1 binding activity in the vector control transfectants (Figure 8 ), indicating signi®cant presence of c-Jun both in the presence and the absence of dominant negative Jun. These results in agreement with others (Brown et al., 1993 (Brown et al., , 1996 , support the conclusion that TAM-induced AP-1 inhibition was due not to prevention of AP-1/DNA binding but to the formation of DNA bound TAM-containing heterodimers.
Discussion
Elevated AP-1 and NF-kB appear to be important in maintaining more progressed phenotypes in HPV immortalized human keratinocytes
In this study, we have demonstrated using two independent origins of cell lines that either AP-1 or NF-kB activation or both may contribute to maintaining the more progressed phenotypes in HPV immortalized human keratinocytes. Transcription factor activities showed 3 ± 5-fold elevations over early stages. Overexpression of a mutant c-jun driven by a human keratin 14 promoter inhibited AP-1 and NF-kB transactivation speci®cally and partially reverted the phenotype of anchorage-independence. Whether greater suppression of anchorage independence will occur with higher levels of TAM expression will be important to determine. Cross-interaction of transcription factors including AP-1 and NF-kB subfamilies has been described (Stein et al., 1993; Thanos et al., 1995) . AP-1 family members c-Jun or c-Fos but not Jun B or Jun D and NF-kB family member p65 but not p50 or c-rel cross-interact and synergize in AP-1 or NF-kBdependent gene transactivation (Stein et al., 1993) . The interaction involves the bZip domain of c-Jun or c-Fos and the rel homology domain of p65. The p65/c-Jun or p65/c-Fos interaction appears speci®c for the AP-1/ TRE element (Stein et al., 1993) . Deletion of the Nterminal transactivation domain of c-Jun similar to that in TAM67 caused complete loss of transcriptional enhancement of NF-kB responsive promoters (Stein et al., 1993) . Our present results indicate that in addition to c-Jun and c-Fos, Fra-1 and Fra-2 of the Fos family proteins may be also involved in the interaction and signaling for AP-1 and NF-kB transactivation, since these two proteins were found in the more progressed but not the less progressed keratinocyte lines. The exact role of this cross-link between AP-1 and NF-kB subfamilies in neoplastic progression or its inhibition is not known but the bZip domain implicated in the cJun-p65 interaction is intact in TAM67. We have demonstrated in the mouse JB6 skin cell model that AP-1 activation appears to be causally related to tumor promoter induced transformation (Dong et al., 1994) . Using an AP-1 and NF-kB double reporter JB6 mouse epidermal cell line, we have observed that both AP-1 and NF-kB are activated during tumor promoter induced transformation and both transcription factors are transrepressed by small molecule inhibitors of either (Li et al., 1997) . Although AP-1 and NF-kB can synergize in either direction, the fact that NF-kB transactivation occurs ®rst in the JB6 mouse skin cell model, suggests an NF-kB-to-AP-1 direction in tumor promoter induced transformation, but the possibility of separate pathways is not excluded. Implication of either or both transcription factors in keratinocyte progression has been further supported by our observation that dominant negative jun expression in a mouse keratinocyte papilloma cell line blocked not only AP-1 but also NF-kB activation when invasion was also blocked (Dong et al, 1997) . Thus alterations in the expression of target genes regulated by AP-1 and/or NF-kB transactivation may determine the phenotypic changes seen in the more progressed cell lines.
E6/E7 expression is not the factor driving progression E6/E7 oncoproteins are necessary for transformation and immortalization of HPV immortalized keratinocytes (Munger et al., 1989b) . HPV16 and HPV18 encoded E6 and E7 interact with tumor suppressor proteins p53 and pRb respectively to bring about their inactivation (Munger et al., 1989a) . The HPV16 E7 protein interacts with and transactivates the AP-1 family of transcription factors (Antinore et al., 1996) . P-labeled collagenase AP-1 oligonucleotide probe and separated by 6% acrylamide gel electrophoresis. Supershift of AP-1 was performed with the same nuclear extracts as lanes 1 ± 4 (lanes 7 ± 10) after reaction with Nterminal c-Jun antibody (4 mg per reaction). Speci®city of AP-1 binding was veri®ed by competition using 1006excess of cold collagenase oligonucleotide (c). F: free probe control. Data present one of duplicate EMSA's using separate nuclear extracts When E7 was co-expressed with c-Jun, it up-regulated a Jun-responsive promoter. Mutant c-Jun (TAM67) decreased the transformation induced by E7 and ras co-expression (Antinore et al., 1996) , raising the possibility that E7 might stimulate progression by enhancing AP-1 transactivation. Our present results indicate that elevation of E7 expression, E7-related Rb inactivation, or E6-related p53 inactivation, are not the factors driving progression in the HPV 16 and HPV18 immortalized human keratinocyte series. This is based on the fact that a human p53 promoter driven luciferase reporter showed no change in p53 dependent transcriptional activity in the more progressed cell lines 16RH and 18 v-fos compared to the less progressed but immortalized lines, and that E7 expression which produces Rb inactivation, remained constant in all the progression variants of the E6/E7 immortalized HPV16 series and HPV-18 v-fos transformed cell series. This agrees with recent reports of similar E7 protein levels in these calcium resistant and calcium sensitive HPV16 immortalized cell lines (Greenhalgh et al., 1995; Wilding et al., 1996) . Together, these results suggest that although E7 interaction and transactivation of AP-1 may be involved in the immortalization, the elevation of AP-1 transactivation in more progressed stages is not attributable to elevated E7.
K-14 driven TAM gene speci®cally inhibits elevated levels of transcription factor activities Keratins 14 and 5 are major proteins expressed in the mitotically active basal epidermal cells and the genes are actively transcribed in cultured human keratinocytes (Stellmach et al., 1991) . Our present data show that Fos family is related to the AP-1 transactivation and a mutant c-jun eectively inhibits both AP-1 and NF-kB transactivation in the more progressed human keratinocytes under the control of a human K14-promoter. Relative low levels of TAM (compared to endogenous Jun) were required for substantial transcription factor transrepression, similar to the observation with mouse keratinocytes (Dong et al., 1997) . It is noteworthy that K14-driven TAM expression in the HPV-immortalized keratinocytes did not inhibit the AP-1 and NF-kB transactivation levels seen in the less progressed cell lines but eciently inhibited thè elevated' AP-1 and NF-kB activation seen in the more progressed cell lines, 16RH and 18 v-fos. A similar selectivity was seen in mouse JB6 cells expressing TAM67. These cells were inhibited for tumor promoter induced but not for basal AP-1 activity (Dong et al., 1994) . The molecular basis for this selectivity is unknown but low rather than no AP-1 activation in the presence of TAM67 might re¯ect the low activity of TAM-Jun or TAM-Fos heterodimers (Brown et al., 1996) . The selective inhibition of elevated or induced activity could have utility for the application of such dominant negative AP-1 reagents to the prevention or treatment of cancer.
In conclusion, these results suggest for the ®rst time a role for AP-1 and/or NF-kB transactivation in the progression of HPV-immortalized human keratinocytes toward tumor phenotype. Whether this involves functional cooperativity between the two transcription factor families will be important to determine.
Materials and methods

Cell lines
HPV16 E6/E7 immortalized human keratinocyte cell lines which are sensitive to calcium-induced dierentiation (low and high passage, designated 16SL with passage range 22 ± 34 and 16SH with passage range 108 ± 122) and cell lines which are resistant to calcium-induced dierentiation (low and high passage, designated 16RL with passage range 22 ± 31 and 16RH with passage range 133 ± 148) were obtained by transfection with HPV16 E6/E7 open reading frames as described (Hawley-Nelson et al., 1989; Wilding et al., 1996) . This cell series was maintained in calcium/serum free KGM with 50 mg/ml gentamicin, 0.5 mg/ml hydrocortisone, 5 mg/ ml insulin, 7.5 mg/ml bovine pituitary extract, and human recombinant epithelial growth factor 0.1 ng/ml. An independent pair, the HPV18 immortalized human keratinocyte cell line (18, transfected with HVP18 genome with passage range 50 ± 66) and transformed human keratinocyte cell line (18 v-fos, co-transfected with HVP18 genome and FBJ/R vfos gene with passage range 52 ± 76) were maintained in a 1 : 1 KGM/DMEM medium as previously described (Pei et al., 1993; Schlegel et al., 1988) . The phenotypes of these two progression series are summarized in Figure 1 .
Plasmids
The collagenase AP-1-luciferase reporter, HIV-NF-kB luciferase reporter and p53 luciferase reporter (PG13) (Kern et al., 1992) were the same as previously reported (Dong et al., 1994) . HIV-NFkB-luciferase reporter driven by a 197 HIV-1 LTR fragment containing two NF-kB binding sites (from Dr D Derse, NCI) (Carroll et al., 1991) . pCEP4 with a hygromycin resistance gene was obtained from Invitrogen Co,. A human K14 promoter driven mutant cjun (TAM67) vector was constructed by inserting the TAM67 sequence into the vector pGem3z which contains a human keratin 14 promoter and a human growth hormone segment (Dong et al., 1997) . Vector pGem3z with the human keratin 14 promoter and a 3' human growth hormone segment was a kind gift of Dr E Fuchs at the University of Chicago. A plasmid containing the b-galactosidase gene driven by a CMV promoter was obtained from CLON-TECH Laboratories, Inc. (Palo Alto, CA).
Reporter transfection and luciferase assay
Cells were co-transfected by the LipofectAMINE method using luciferase reporter DNA, and b-galactosidase reporter plasmids. Cells were cultured in KGM (HPV16 E6/E7 immortalized series) or KGM/DMEM medium (HPV18 immortalized series) for 24 ± 36 h following transfection. Luciferase activity was measured by a luminometer (Monolight 2010, Analytical Luminescence Laboratory, San Diego, CA) using 100 ml of whole cell lysate and the same volume of luciferase assay reagent (Promega, Madison, WI). An aliquot of the same cell lysate of each cell line was used for measurement of b-galactosidase activity for normalization of luciferase activity. For analysis of the inhibitory eect of dominant negative c-Jun (TAM67) expression on AP-1 or NF-kB transactivation, 16 RH or 18 v-fos cell lines were co-transfected with TAM67 plasmid or control vector (pGem3z) with b-galactosidase reporter by LipofectAMINE. Cells were then cultured in complete KGM or KGM:DMEM medium for 20 ± 24 h and luciferase activity was measured as described above.
Establishment of stable 16RH and 18 v-fos mutant c-jun transfectants
In order to determine the eect of mutant c-Jun (TAM) expression on the transformation phenotypes of the 16RH and the HPV18 v-fos transformed (18 v-fos) cells, stable K14-TAM transfectants of both cell lines were generated. Stable transfection by LipofectAMINE was the same as described (Li et al., 1995 (Li et al., , 1996 . Brie¯y, 5610 6 cells of each cell line were grown in 100 mm cell culture dishes and cultured for 24 h followed by transfection with 20 mg K14-TAM67 plasmid and 2 mg hygromycin resistance vector pCEP4 and 40 mg LipofectAMINE in 6 ml serum-reduced OPTI-EMEM (Gibco). Duplicate dishes from the same cell line were co-transfected with the control vector pGem3z and pCEP4 hygromycin resistance vector and resistant clones were selected. Seventy two hours after transfection, cells were plated and hygromycin B (25 mg/ml) was added to the culture 4 ± 6 h later. Thirty to 40 clones from each transfection were pooled, passaged for 2 ± 5 passages, and used for measurement of dominant negative c-Jun expression by Western blotting and anchorage-independent growth by soft agar assay.
Immunoprecipitation and Western blotting
For immunoprecipitations, cell lysates (60 mg total protein) were incubated with 2 mg of rabbit antibody against C-terminal mouse c-Jun and 20 ml protein ASepharose beads (Pharmacia Biotech Co., Piscataway, NJ) overnight at 48C. The bound protein was washed, eluted by heating for 10 min with 50 mM DTT at 708C for 10 min and mixed with 106loading buer and size separated in a 12.5% acrymide SDS ± PAGE. The protein was transferred to an Immobilon-P PVDF protein blot membrane (Millipore Co., Bedford. MA) and blocked at room temperature for 2 h, incubated overnight at 48C with 1 : 300 dilution of goat antibody to mouse c-Jun (Santa Cruz Biotechnology Co., Santa Cruz, CA) and incubated 2 h at room temperature with a 1 : 5000 dilution of peroxidase conjugated anti-goat IgG antibody (Boehringer Mannheim Co., Indianapolis, IN). The blots were visualized with the ECL Western blot detection solution (Amersham Co., Arlington Heights, IL).
RT-PCR
RNA preparations were treated with RNase-free DNaseI before RT-PCR was performed. cDNA was synthesized in a reaction volume of 20 ml containing 0.1 mg total RNA, 100 pmol of random hexadeoxynucleotides (Promega Co., Madison, WI), 50 mM Tris-HCl, pH 8.3, 75 mM KCl, 10 mM DTT, 500 mM of each of the dNTPs, 20 U RNase inhibitor (rRNasin, Promega) and 200 U moloney murine leukemia virus reverse transcriptase (MMLV-RT, Gibco/ BRL, Gaithersburg, MD). After 10 min at room temperature it was incubated at 428C for 60 min RNA samples from each cell line without RT served as negative controls. For PCR reactions, 5 ml cDNA products were mixed with PCR reaction buer (Promega) 5.0 mM MgCl 2 , 50 mM of each dNTP, 2.0 units Taq DNA polymerase (Promega), and 0.1 mM of each of the following primers. For ampli®cation of the HPV16 E7 region, we used HPV16 E7: 5'-TGC ATG GAG ATA CAC CTA CAT TGC -3', nt 562 ± 585 (sense) and 5'-GGT TTC TGA GAA CAG ATG GGG C -3', nt 854 ± 833 (antisense). For ampli®cation of the HPV18 E6/E7 region, used HPV18 E6: 5'-AAC ACG GCG ACC CTA CAA GCT-3', nt 120 ± 140 (sense) and HPV18E7: 5'-AAT GTT GCC TTA GGT CCA TGC-3' nt 607 ± 587 (antisense) (Czegledy et al., 1994) . HPV16 primers were used in the HPV-16 E6/E7 immortalized cell series and HPV18 primers were used for PCR with HPV-18 immortalized cell lines. Conditions for cycling: 948C 30 s, 588C 30 s and 688C 1 min; 30 cycles. For radioactive quantitation, dCTP was replaced by 1.25 mCi [
32 Pd]CTP in each reaction and the product radioactivity was measured by a radioactivity detector at 0 ± 40 cycles.
Nuclear protein preparation
Immortalized human keratinocytes (5610 7 ) grown in a 100 mm tissue culture dish were collected by scraping with sterilized rubber policeman, washed three times with PBS and resuspended in 0.5 ml cell lysis buer containing: 50 mM KCl, 0.5% NP40, 25 mM HEPES, pH 7.8, 2 mM PMSF, 2 mg/ml leupeptin, 4 mg/ml aprotinin and 100 mM DTT. The cell lysate was centrifuged at 48C for 1 min and the pellets were washed with 0.3 ± 0.5 ml washing buer once by centrifuging at 48C for 1 min. The cell nuclei were resuspended in 50 ± 100 ml nuclear protein extraction buer containing: 500 mM KCl, 25 mM HEPES, pH 7.8, 10% glycerol, 1 mM PMSF, 1 mg/ml leupeptin, 2 mg/ml aprotinin and 100 mM DTT. The nuclear extract was centrifuged at 48C for 5 min and the supernatants were saved as nuclear protein extract and stored at 7708C. The protein concentration of the nuclear extract was measured before EMSA analysis.
EMSA AP-1 binding oligonucleotide probe, 5'-CGCTTGAT-GAGTCAGCCGGAA-3' and NF-kB binding oligonucleotide probe, 5'-AGTTGAGGGGACTTTCCCAGGC-3 were synthesized and end-labeled with 32 P-dATP. Three micrograms of nuclear protein extracted from human keratinocytes at each neoplastic progression stage were incubated in 20 ml DNA binding buer containing 1.5 mg Poly dI.dC, 40 mM Tris (pH 7.5), 120 mM KCL, 8% Ficoll, 4 mM EDTA and 15 mM DTT. The reaction mixture was incubated on ice for 10 min, then further incubated for 20 min at room temperature after adding 5610 4 c.p.m. 32 P-labeled oligonucleotide probes. The DNA-protein complexes were resolved in a 6% nondenaturing acrylamide gel and electrophoresed for 1.5 ± 2 h at room temperature. The gel was dried and exposed to X-ray ®lm at 7708C overnight. For supershift, the nuclear extracts were ®rst incubated with antibody to AP-1 subunits (Santa Cruz Co., sc-45x for c-Jun, sc-46x for Jun B, sc-74x for Jun D, sc-52x for c-Fos, sc-605x for Fra-1 and sc-604x for Fra-2) at room temperature for 20 min then further incubated with 32 P-labeled DNA oligonucleotides for another 20 min. The DNA-protein complexes were resolved in a 6% nondenaturing polyacrylamide gel and electrophoresed at room temperature as described above.
Anchorage-independent growth assay
Anchorage-independent growth in TAM67 transfectants was assayed in stably transfected 16RH and 18-fos cell lines. Ten thousand cells from TAM67 transfected and the pGemsz control vector transfected cell line as well as the parental 16RH or 18-fos cell line were suspended in 1.5 ml 0.4% agar in KGM or KGM : DMEM mix medium over 5 ml 0.6% agar KGM medium. The cultures were maintained in a 378C incubator at 10% CO 2 for 21 days and anchorage independent colonies greater than 25 cells were scored by a computerized image analyser.
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